LINC02351: A Long Intergenic Non-Protein Coding RNA (G105371011)

Target Name: LINC02351

NCBI ID: G105371011

LINC02351

Other Name(s): long intergenic non-protein coding RNA 2351 | Long intergenic non-protein coding RNA 2351, transcript variant 1

LINC02351: A Long Intergenic Non-Protein Coding RNA

Non-Protein-Coding RNAs (NP-CsRNAs) have emerged as a promising source of new biomarkers and drug targets in recent years. These RNAs are generated from genomic regions that are not known to code for proteins, but can be expressed and stabilized in the cell. One of the defining features of NP-CsRNAs is their ability to accumulate in the cell and to be translationally processed into functional proteins.

One of the most well-studied NP-CsRNAs is LINC02351, which was identified in the ENCODE (Encyclopedia of DNA Elements) database. LINC02351 is a long intergenic non-protein coding RNA (lncRNA), which means that it is longer than most proteins and that it does not have a protein coding gene. Despite its non-protein coding nature, LINC02351 is expressed in the cell and can be translated into a functional protein using RNA interference (RNAi) technology.

The LINC02351 gene is located on chromosome 16 at position 13182.2 and has a length of approximately 2391 nucleotides. It is characterized by a unique open reading frame (ORF) that spans over 1.5 kilobases (kb) and contains multiple exons that are predominantly expressed in the brain.

Expression of LINC02351

LINC02351 is a highly expressed gene in the brain and has been observed to be expressed in various brain regions, including the prefrontal cortex, the amygdala, and the hippocampus. It is also expressed in other tissues and organs, including the heart, the lungs, and the liver.

The expression of LINC02351 has been studied using RNAi technology, which involves the introduction of a specific RNA molecule into the cell to knockdown (reduce the amount of) the gene expression. RNAi studies have shown that LINC02351 is highly stable and can be effectively knockdown using RNAi.

Drug targeting LINC02351

The unique expression pattern of LINC02351 and its stability make it an attractive drug target. LINC02351 has been shown to play a role in various cellular processes, including cell survival, metabolism, and inflammation.

One potential mechanism by which LINC02351 could be targeted is through its role in cell survival. LINC02351 has been shown to be involved in the regulation of cell apoptosis, which is the process by which cells die when they are no longer needed.

Additionally, LINC02351 has been shown to be involved in the regulation of metabolism and inflammation. It has been shown to be involved in the regulation of glucose metabolism and has been shown to play a role in the regulation of inflammation.

Another potential mechanism by which LINC02351 could be targeted is through its role in cell-cell signaling. LINC02351 has been shown to be involved in the regulation of cell-cell interactions and has been shown to play a role in the regulation of cell signaling.

Conclusion

LINC02351 is a long intergenic non-protein coding RNA that has been identified in the ENCODE database and has been shown to be expressed in the cell and to play a role in various cellular processes. Its unique expression pattern and stability make it an attractive drug target and a potential biomarker for various diseases. Further research is needed to fully understand the role of LINC02351 in cellular processes and to develop effective therapies based on this RNA.

Protein Name: Long Intergenic Non-protein Coding RNA 2351

The "LINC02351 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02351 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets